123
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Treatment Outcome of Tubercular Uveitis in a High TB and HIV Setting: A Prospective Cohort Study

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 4839-4846 | Published online: 30 Dec 2021

References

  • Agrawal R, Agarwal A, Jabs DA, et al. Standardization of nomenclature for ocular tuberculosis - results of Collaborative Ocular Tuberculosis Study (COTS) workshop. Ocul Immunol Inflamm. 2019;12:1–11. doi:10.1080/09273948.2019.1653933.
  • Gupta V, Gupta A, Rao NA. Intraocular tuberculosis - an update. Surv Ophthalmol. 2007;52(6):561–587. doi:10.1016/j.survophthal.2007.08.015
  • Gupta V, Arora S, Gupta A, Ram J, Bambery P, Sehgal S. Management of presumed intraocular tuberculosis: possible role of the polymerase chain reaction. Acta Ophthalmol Scand. 1998;76(6):679–682. doi:10.1034/j.1600-0420.1998.760609.x
  • Sudheer B, Lalitha P, Kumar AL, Rathinam S. Polymerase chain reaction and its correlation with clinical features and treatment response in tubercular uveitis. Ocul Immunol Inflamm. 2018;26(6):845–852. doi:10.1080/09273948.2017.1287925
  • Arora SK, Gupta V, Gupta A, Bambery P, Kapoor GS, Sehgal S. Diagnostic efficacy of polymerase chain reaction in granulomatous uveitis. Tuber Lung Dis. 1999;79(4):229–233. doi:10.1054/tuld.1999.0210
  • Gupta B, Agrawal R, Swampillai AJ, et al. Ocular manifestations of tuberculosis: an update. Expert Rev Ophthalmol. 2016;11(2):145–154. doi:10.1586/17469899.2016.1152887
  • Alli HD, Ally N, Mayet I, Dangor Z, Madhi SA. Global prevalence and clinical outcomes of tubercular uveitis: a systematic review and meta-analysis. Surv Ophthalmol. 2021. doi:10.1016/j.survophthal.2021.10.001
  • Manousaridis K, Ong E, Stenton C, Gupta R, Browning AC, Pandit R. Clinical presentation, treatment, and outcomes in presumed intraocular tuberculosis: experience from Newcastle upon Tyne, UK. Eye. 2013;27(4):480–486. doi:10.1038/eye.2013.11
  • Shakarchi FA. Mode of presentations and management of presumed tuberculous uveitis at a referral center. Iraqi Postgrad Med J. 2015;14(1):91–95.
  • Chung CY, Li KKW. The efficacy of latent tuberculosis treatment for immunocompetent uveitis patients with a positive T-SPOT.TB test: 6-year experience in a tuberculosis endemic region. Int Ophthalmol. 2018;38(6):2273–2282. doi:10.1007/s10792-017-0716-y
  • Balne PK, Modi RR, Choudhury N, et al. Factors influencing polymerase chain reaction outcomes in patients with clinically suspected ocular tuberculosis. J Ophthalmic Inflamm Infect. 2014;4(1):10. doi:10.1186/1869-5760-4-10
  • Ang M, Hedayatfar A, Wong W, Chee SP. Duration of anti-tubercular therapy in uveitis associated with latent tuberculosis: a case-control study. Br J Ophthalmol. 2012;96(3):332–336. doi:10.1136/bjophthalmol-2011-300209
  • Ng KK, Nisbet M, Damato EM, Sims JL. Presumed tuberculous uveitis in non-endemic country for tuberculosis: case series from a New Zealand tertiary uveitis clinic. Clin Exp Ophthalmol. 2017;45(4):357–365. doi:10.1111/ceo.12881
  • Krassas N, Wells J, Bell C, Woodhead M, Jones N. Presumed tuberculosis-associated uveitis: rising incidence and widening criteria for diagnosis in a non-endemic area. Eye. 2018;32(1):87–92. doi:10.1038/eye.2017.152
  • Agrawal R, Gunasekeran DV, Grant R, et al. Clinical features and outcomes of patients with tubercular uveitis treated with antitubercular therapy in the Collaborative Ocular Tuberculosis Study (COTS)-1. JAMA Ophthalmol. 2017;135(12):1318–1327. doi:10.1001/jamaophthalmol.2017.4485
  • Agarwal A, Agrawal R, Raje D, et al. Twenty-four month outcomes in the Collaborative Ocular Tuberculosis Study (COTS)-1: defining the “Cure” in ocular tuberculosis. Ocul Immunol Inflamm. 2020:1–9. doi:10.1080/09273948.2020.1761401.
  • Alvarez GG, Roth VR, Hodge W. Ocular tuberculosis: diagnostic and treatment challenges. Int J Infect Dis. 2009;13(4):432–435. doi:10.1016/j.ijid.2008.09.018
  • Vos AG, Wassenberg MWM, de Hoog J, Oosterheert JJ. Diagnosis and treatment of tuberculous uveitis in a low endemic setting. Int J Infect Dis. 2013;17(11):e993–e999. doi:10.1016/j.ijid.2013.03.019
  • Agrawal R, Gupta B, Gonzalez-Lopez JJ, et al. The role of anti-tubercular therapy in patients with presumed ocular tuberculosis. Ocul Immunol Inflamm. 2015;23(1):40–46. doi:10.3109/09273948.2014.986584
  • Bansal R, Gupta A, Gupta V, Dogra MR, Bambery P, Arora SK. Role of anti-tubercular therapy in uveitis with latent/manifest tuberculosis. Am J Ophthalmol. 2008;146(5):772–779. doi:10.1016/j.ajo.2008.06.011
  • Tomkins-Netzer O, Leong BCS, Zhang X, Lightman S, McCluskey PJ; Sydney-London Latent Ocular TB Study Group. Effect of antituberculous therapy on uveitis associated with latent tuberculosis. Am J Ophthalmol. 2018;190:164–170. doi:10.1016/j.ajo.2018.03.032
  • UNAIDS programme coordinating board sees South Africa’s AIDS response first-hand; 2018. Available from: https://www.unaids.org/en/resources/presscentre/featurestories/2018/november/pcb-field-visit-south-africa. Accessed December 11, 2020.
  • World Health Organization. Global tuberculosis report 2019. Available from: http://www.who.int/tb/publications/global_report/en/. Accessed June 1, 2020.
  • Centers for disease control and prevention. Fact sheets | Testing & Diagnosis | Fact sheet - Tuberculin skin testing | TB. CDC; 2020. Available from: https://www.cdc.gov/tb/publications/factsheets/testing/skintesting.htm. Accessed November 18, 2021.
  • Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516. doi:10.1016/j.ajo.2005.03.057
  • Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi:10.1016/j.jbi.2008.08.010
  • Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi:10.1016/j.jbi.2019.103208
  • Basu S, Wakefield D, Biswas J, Rao NA. Pathogenesis and pathology of intraocular tuberculosis. Ocul Immunol Inflamm. 2015;23(4):353–357. doi:10.3109/09273948.2015.1056536
  • Kee AR, Gonzalez-Lopez JJ, Al-Hity A, et al. Anti-tubercular therapy for intraocular tuberculosis: a systematic review and meta-analysis. Surv Ophthalmol. 2016;61(5):628–653. doi:10.1016/j.survophthal.2016.03.001
  • Huebner RE, Schein MF, Bass JB. The tuberculin skin test. Clin Infect Dis. 1993;17(6):968–975. doi:10.1093/clinids/17.6.968
  • Leidl L, Mayanja-Kizza H, Sotgiu G, et al. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. Eur Respir J. 2010;35(3):619–626. doi:10.1183/09031936.00045509
  • Patel SS, Saraiya NV, Tessler HH, Goldstein DA. Mycobacterial ocular inflammation: delay in diagnosis and other factors impacting morbidity. JAMA Ophthalmol. 2013;131(6):752–758. doi:10.1001/jamaophthalmol.2013.71
  • Gunasekeran DV, Gupta B, Cardoso J, Pavesio CE, Agrawal R. Visual morbidity and ocular complications in presumed intraocular tuberculosis: an analysis of 354 cases from a non-endemic population. Ocul Immunol Inflamm. 2018;26(6):865–869. doi:10.1080/09273948.2017.1296580
  • Agrawal RM, Gunasekeran DVM, Agarwal AM, et al. Visual morbidity in ocular tuberculosis - Collaborative Ocular Tuberculosis Study (COTS)-1: report #6. Ocul Immunol Inflamm. 2020:1–9. doi:10.1080/09273948.2020.1774905.